Please join us for a PMC and MIT Center for Biomedical Innovation Forum

Personalized Medicine and CNS Disorders:
The Changing Landscape of Mental and Neurological Illness

Thursday, August 17, 2006
1:00 p.m. - 5:00 p.m.
Cambridge, MA

This half-day seminar will explore how new diagnostic tools are changing
psychotropic and neurological drug discovery and development and the impact
on patients with CNS (Central Nervous System) disorders.

Agenda | Event Details | Registration | Hotel Information

Concept

As the study of genetics and the discovery of biomarkers reshape understanding of human behavior, new diagnostic tools are also changing the way psychotropic and neurological drugs are discovered and developed and also how patients with CNS (Central Nervous System) disorders are treated. This evolving paradigm change made possible by advances in science and technology promises to improve the lives of the millions of people who suffer from depression, Alzheimer’s Disease, schizophrenia, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder, stroke and other brain disorders. In partnership with the Center for Biomedical Innovation at MIT, the Personalized Medicine Coalition will hold a half-day seminar on the subject of personalized medicine and CNS on the afternoon of August 17th in Cambridge, Massachusetts, as part of the 5th Annual Celebration of Biotechnology in Kendall Square, that explores how personalized medicine is changing the landscape of mental and neurological illnesses from the points of view of the pharmaceutical industry, diagnostic companies, practicing clinicians, government regulators, and insurance companies.

Speakers will address the following topics:

  • How is a developing molecular understanding of the brain changing conceptions about mental and neurological illness?
  • How are new conceptions of personalized medicine altering the discovery, development, and prescription of CNS drugs, including the possible introduction of preventive interventions in the future?
  • How can more sophisticated diagnostic instruments improve the treatment of patients with mental and neurological illnesses?
  • What is the likelihood that more targeted therapies without serious side effects will be introduced in the near future?
  • How are psychiatrists and neurologists currently “personalizing” the treatment of patients, and what is required to accelerate the introduction of new treatments for CNS disorders?
  • How will FDA’s “Critical Path” initiative and other Agency efforts change the way CNS drugs are developed, reviewed, and regulated?
  • Will personalized medicine approaches to mental and neurological illness change the way insurance companies reimburse patients, doctors, and hospitals for the treatment of CNS disorders?

Biomedical Innovation Forum Agenda*

Session 1: Pharmaceutical R&D

1:00-1:20

CNS Drugs and Pharmaceutical R&D - Targeted Therapies
Frank Douglas, M.D., Ph.D. – Session Chair
Executive Director, CBI, MIT

Economics of Stratified Medicine
Ernst Berndt, Ph.D. – Session Chair
Louis V. Seley Professor of Applied Economics, Sloan School of Management, MIT

1:20-1:40

Perspectives on CNS Drug Discovery and Development
Scott Gottlieb, M.D.
Deputy Commissioner of Medical and Scientific Affairs, FDA

1:40-2:00

Perspectives on CNS Drug Discovery and Development
Stephen Furlong, Ph.D.
Director, Discovery Medicine, AstraZeneca

2:00-2:20

Perspectives on CNS Drug Discovery and Development
Eiry W. Roberts, MB (Hons) BS, BSc MRCP, AFPM
Research Technology & Exploratory Medicine, Eli Lilly and Company

2:20-2:50

Panel Discussion
Frank Douglas, M.D., Ph.D. – Moderator
Executive Director, CBI, MIT

2:50-3:10

Break and Refreshments

 
Session 2: Clinical Practice

3:10-3:30

The Practice of Personalized Neurology and Psychiatry
Gualberto Ruano, M.D., Ph.D. – Session Chair
President and CEO, Genomas

3:30-3:50

The Role of a Standardized Brain Database in Personalized Medicine
Evian Gordon, M.D., Ph.D.
Chairman and CEO, The Brain Resource Company

3:50-4:10

The Clinicians’ Perspective on Personalized Approaches to Treatment of Mental Illness
Scott Rauch, M.D.
Associate Chief of Psychiatry for Neuroscience Research, Massachusetts General Hospital

4:10-4:30

A Payer’s Perspective on Personalized CNS Diagnosis and Treatments
David Whitehouse, M.D.
Chief Medical Officer, Strategy & Innovation, United Behavioral Health

4:30-5:00

Panel Discussion
Gualberto Ruano, M.D., Ph.D. – Moderator
President and CEO, Genomas

5:00-6:00

Wrap Up & Light Refreshments
Time for phone calls and emails

*This two-part forum also includes a morning session: Vaccines: Opportunities and Barriers Across the Value Chain. (Click here to view the agenda)

This event is being held as part of the 5th Annual Celebration of Biotechnology in Kendall Square, an evening celebrating one of the most concentrated biotechnology clusters in the world.

Event Details:

MIT Biomedical Innovation Forum
Date: August 17, 2006
Time: 8:00 a.m. - 5:00 p.m.
Location: MIT Stata Center, Building 32 [ MAP ]
Cambridge, MA

The 5th Annual Celebration of Biotechnology
Date: August 17, 2006
Time: 6:00 p.m. - 9:00 p.m.
Location: Broad Institute of MIT and Harvard
Seven Cambridge Center, Kendall Square
Cambridge, MA

     

PMC acknowledges the support of the following companies:

Registration:

Click here to register for the MIT Biomedical Innovation Forum.

Click here to register for the 5th Annual Celebration of Biotechnology in Kendall Square evening celebration.
(PLEASE NOTE: You must register separately for the forum and the evening celebration.)

Cost:
There is no charge to attend this event, but registration is required.

Hotel Information:

Hotel@MIT
617-577-0200
20 Sydney Street
Cambridge, MA 02139
Discounted rate available (ask for MIT rate)